Short answer
Kura Oncology, Inc. (KURA) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $18M (up 29.5% year over year) with net income of −$73M.
Q1 2026 key financials · XBRL
- Revenue
- $18M
- +29.5% YoY
- Net income
- −$73M
- −27.7% YoY
- Operating margin
- -431.5%
- EPS (diluted)
- −$0.83
- −25.8% YoY
Source: XBRL data from the Kura Oncology, Inc. (KURA) Q1 2026 10-Q on SEC EDGAR. USD.
Kura Oncology, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material-change disclosure or quarter-specific new risk identified in provided excerpt
- Commercial launch risk from limited experience selling, marketing, and distributing approved drugs
- FDA post-approval scrutiny triggered by broader real-world exposure and spontaneous adverse-event reports
- Competitive risk from FDA-approved revumenib and emerging menin inhibitors in NPM1-mutated AML
- Reimbursement risk from Medicare negotiation and government efforts to reduce prescription-drug spending
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kura Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.